Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02559869 · ClinicalTrials.gov registry record

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis

A clinical trial of Amyotrophic Lateral Sclerosis (ALS), sponsored by Massachusetts General Hospital.

Completed
Registry status
86
Enrollment target
2
Study locations

NCT02559869: Completed study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Massachusetts General Hospital.

NCT02559869 is a study of Amyotrophic Lateral Sclerosis (ALS) that has completed, run by Massachusetts General Hospital. The registered enrollment target is 86 participants, below the 297-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02559869, a study of Amyotrophic Lateral Sclerosis (ALS), has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
86 participants
Enrollment target
2
Study locations

Study Summary

This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences between different disease phenotypes. This pilot project is tailored to produce imaging tools that will allow researchers to conduct future ALS clinical trials more efficiently which may in turn impact the pace for ALS drug discovery.

Primary Outcome

Aim 1 will be accomplished by obtaining \[18F\] GE-180 PET imaging from 25 people with ALS compared to 25 age, gender, and binding affinity matched healthy volunteers.

Interventions

  • DRUG [18F] GE-180

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

Texas

  • Houston Methodist Hospital - Houston

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2015-11
Est. Completion 2019-06-28
Massachusetts General Hospital

2,032 total trials

What the finished NCT02559869 record still lists

NCT02559869 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 297-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (71% lower).

The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 1 intervention - of which [18F] GE-180 is the first listed.

NCT02559869 reports a single indexed study location in Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT02559869 about?

NCT02559869 is a clinical study titled "Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis". This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences between different disease phenotypes. This pilot project is tailored to pr...

What is the current status of trial NCT02559869?

This trial is currently completed. The enrollment target is 86 participants. The study started on 2015-11. Estimated completion is 2019-06-28.

What conditions does trial NCT02559869 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).

What interventions are being tested in trial NCT02559869?

The interventions under investigation include: [18F] GE-180 (DRUG).

Who is sponsoring clinical trial NCT02559869?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02559869 being conducted?

This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyotrophic Lateral Sclerosis (ALS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02559869's enrollment target sits among peer trials

86 11th of 18 higher than 8 of 18 other Amyotrophic Lateral Sclerosis (ALS) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis (ALS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02559869, the US trial registry maintained by the National Library of Medicine. NCT02559869 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.